The product, manufactured at Farmak Group’s EU GMP-certified sterile facilities, is supplied to NHS hospitals starting 1 June 2025 following a successful national tender award. The product is indicated in adults and children for the rapid treatment of severe depletion or malabsorption of water-soluble vitamins B and C. Clinical use includes: • Thiamine deficiency due to alcoholism, including the risk of Wernicke’s encephalopathy • Recovery after acute infections or surgical procedures • Psychiatric conditions • Maintenance therapy during chronic intermittent haemodialysis Producing high-potency vitamin B and C injectables involves complex manufacturing processes. These formulations are typically supplied as two separate ampoules that must be combined under sterile conditions, requiring advanced aseptic production and stringent quality control. Additionally, while the product is stable at standard storage conditions (below 25°C), maintaining sterility and formulation integrity across two components adds complexity to both manufacturing and distribution, especially in large-scale hospital supply. This approval comes at a critical time. The UK has experienced ongoing supply constraints for these essential formulations, with NHS Medicine Supply Notifications previously highlighting limited availability of high-potency vitamin combinations. With only a limited number of generic suppliers active in this segment, the availability of this Farmak-manufactured therapy supports continuity of care and improves resilience within hospital supply chains. [press_quote] 📌 View the UK & Ireland portfolio: https://farmak.ch/products-uk-ireland/ 📧 Partner with us: bd@farmak.uk
